CLINUVEL publicly files 20-F to U.S. SEC

• Clinuvel files Form 20-F with U.S. SEC
• Aims to list American Depository Shares (ADS) on Nasdaq
• Upgrade from ADR Level I to Level II
• No capital raise or new share issuance planned

Clinuvel Pharmaceuticals Ltd has filed a Form 20-F Registration Statement with the U.S. Securities and Exchange Commission (SEC), aiming to list American Depository Shares (ADS) on the Nasdaq Stock Market. This upgrade from its current American Depository Receipt (ADR) Level I program to Level II reflects increased investor interest in the company's vitiligo development program. The ADS is expected to trade on Nasdaq with the ticker CUVL. Clinuvel does not plan to raise capital or issue new shares as a result of this upgrade.